J. Hermosilla Fernández, A. Alonso-García, R. Pérez Robles, A. Torrente López, J. Ruiz Travé, N. Navas, J. Cabeza, A. Salmerón García
{"title":"Comirnaty和Spikevax临床解决方案的使用稳定性:辉瑞- biontech和Moderna COVID-19疫苗:从医院药学角度的比较研究","authors":"J. Hermosilla Fernández, A. Alonso-García, R. Pérez Robles, A. Torrente López, J. Ruiz Travé, N. Navas, J. Cabeza, A. Salmerón García","doi":"10.1136/ejhpharm-2023-eahp.38","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"87 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"3PC-015 In-use stability of Comirnaty and Spikevax clinical solutions: Pfizer-BioNTech and Moderna COVID-19 vaccines: a comparative study from a hospital pharmacy perspective\",\"authors\":\"J. Hermosilla Fernández, A. Alonso-García, R. Pérez Robles, A. Torrente López, J. Ruiz Travé, N. Navas, J. Cabeza, A. Salmerón García\",\"doi\":\"10.1136/ejhpharm-2023-eahp.38\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":335223,\"journal\":{\"name\":\"Section 3: Production and Compounding\",\"volume\":\"87 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 3: Production and Compounding\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2023-eahp.38\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 3: Production and Compounding","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2023-eahp.38","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
3PC-015 In-use stability of Comirnaty and Spikevax clinical solutions: Pfizer-BioNTech and Moderna COVID-19 vaccines: a comparative study from a hospital pharmacy perspective